
Opinion|Videos|July 29, 2024
Future Treatment for Anemia of LR-MDS
Author(s)Guillermo Garcia-Manero, MD
An expert on lower-risk MDS discusses how the treatment of anemia is evolving as newer therapies enter the treatment landscape.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What do you see as the future anemia treatment landscape for LR-MDS? What is the impact of newer therapies on the use of ESAs?
- What are the current unmet needs in the treatment of anemia in LR-MDS?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5









































